From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus
Anemia
Management done
N
%
ESA (added or increased dose)
26
52.00
Blood transfusion
7
14.00
Ribavirin stopped
3
6.00
Ribavirin reduced
1
2.00